AI Article Synopsis
- OSCC is a prevalent cancer that contains a specific subpopulation of cancer stem cells characterized by the marker CD133.
- Silencing CD133 in these cancer stem cells was found to enhance their sensitivity to chemotherapy, particularly reducing resistance to the drug cisplatin.
- The study concludes that targeting CD133 effectively improves chemotherapy outcomes by reducing the tumor-initiating capacity of these resistant cancer stem cells in OSCC.
Article Abstract
Background: Oral squamous cell carcinoma (OSCC) is one of the most common cancers in the world. Previously, we enriched a subpopulation of OSCC-derived cancer stem cells (OSCC-CSCs), and identified CD133 as an OSCC-CSC marker.
Method: We determined the function of CD133 on chemosensitivity of oral cancer CSCs by silencing CD133.
Results: Initially, we observed that the expression profile of CD133 in OSCC-side population (OSCC-SPs) cells, which exerted properties of CSCs, was significantly upregulated than that of major population (MPs) cells of OSCCs. The cell viability experiments showed that SPs were more chemoresistant compared with major populations. Importantly, targeting CD133 ameliorated the drug resistance of OSCC-SPs to cisplatin treatment. Targeting CD133 and cisplatin co-treatment led to the maximal inhibition on tumor initiating properties in OSCC-SPs.
Conclusion: Side population cells with CSCs properties existed in OSCCs, and silencing CD133 exhibited a prominent therapeutic effect in enhancing the sensitivity of chemotherapy in OSCC through elimination of CSCs. © 2015 Wiley Periodicals, Inc. Head Neck 38: E231-E238, 2016.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hed.23975 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!